Go or no go? Pandemic looms over FDA timelines
Approval decisions are due for Jazz, Gilead and Galapagos in July, while Glaxo is preparing for a panel.
Rett failure sets up thin pipeline
Newron’s failure in Rett syndrome leaves the late-stage pipeline to GW Pharma, Acadia and Anavex.
Zogenix hands GW a win
A phase III Lennox-Gastaut trial sees Fintepla meet statistical significance but fail the test of clinical relevance.
Upcoming events – Genmab's route to market, and late-stage data for Zogenix
Genmab is seeking data to position tisotumab as its first in-house launch, while Zogenix wants Fintepla to challenge GW in Lennox-Gastaut syndrome.
Upcoming events – Obseva's first fibroid foray and Newron's test in Retts
Obseva awaits data that could make linzagolix third to market, while Newron looks for a starring role in Retts.
Zogenix gets an unwelcome distraction from Fintepla
Spending $250m on Modis gives Zogenix a new rare disease niche, but the timing and the target both look odd.
